Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) have been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $33.25.
A number of equities research analysts recently commented on COLL shares. TheStreet downgraded shares of Collegium Pharmaceutical from a “b-” rating to a “c+” rating in a research report on Monday, April 11th. Needham & Company LLC lifted their price target on shares of Collegium Pharmaceutical from $34.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, April 6th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Thursday, May 19th.
Hedge funds have recently bought and sold shares of the company. Denali Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at approximately $32,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Collegium Pharmaceutical by 52.2% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,161 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 741 shares in the last quarter. Captrust Financial Advisors increased its stake in shares of Collegium Pharmaceutical by 97.5% during the 1st quarter. Captrust Financial Advisors now owns 2,151 shares of the specialty pharmaceutical company’s stock worth $44,000 after purchasing an additional 1,062 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Collegium Pharmaceutical by 233.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,224 shares of the specialty pharmaceutical company’s stock worth $44,000 after purchasing an additional 1,558 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Collegium Pharmaceutical during the 4th quarter worth approximately $187,000.
Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.40). The firm had revenue of $83.80 million during the quarter, compared to analyst estimates of $78.67 million. Collegium Pharmaceutical had a net margin of 15.68% and a return on equity of 3.26%. Collegium Pharmaceutical’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.41 EPS. Analysts expect that Collegium Pharmaceutical will post 4.89 EPS for the current year.
About Collegium Pharmaceutical (Get Rating)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
- Get a free copy of the StockNews.com research report on Collegium Pharmaceutical (COLL)
- Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
- MarketBeat: Week in Review 6/27 – 7/1
- Accolade Moves Higher But Growth Is Slowing
- ZIM Integrated Shipping Services (ZIM): Don’t Miss This Dividend
- RH Gives Good Reason To Get Defensive
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.